You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

NALFON Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Nalfon, and when can generic versions of Nalfon launch?

Nalfon is a drug marketed by Key Therap and Dista and is included in two NDAs.

The generic ingredient in NALFON is fenoprofen calcium. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the fenoprofen calcium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nalfon

A generic version of NALFON was approved as fenoprofen calcium by RISING on July 18th, 2022.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NALFON?
  • What are the global sales for NALFON?
  • What is Average Wholesale Price for NALFON?
Summary for NALFON
Drug patent expirations by year for NALFON
Drug Prices for NALFON

See drug prices for NALFON

Drug Sales Revenue Trends for NALFON

See drug sales revenues for NALFON

Pharmacology for NALFON

US Patents and Regulatory Information for NALFON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Key Therap NALFON fenoprofen calcium CAPSULE;ORAL 017604-003 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dista NALFON fenoprofen calcium TABLET;ORAL 017710-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Key Therap NALFON fenoprofen calcium CAPSULE;ORAL 017604-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Key Therap NALFON fenoprofen calcium CAPSULE;ORAL 017604-004 Jul 21, 2009 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NALFON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Key Therap NALFON fenoprofen calcium CAPSULE;ORAL 017604-003 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Dista NALFON fenoprofen calcium TABLET;ORAL 017710-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Key Therap NALFON fenoprofen calcium CAPSULE;ORAL 017604-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NALFON

See the table below for patents covering NALFON around the world.

Country Patent Number Title Estimated Expiration
Finland 780846 ⤷  Sign Up
Denmark 240677 ⤷  Sign Up
Netherlands 155820 ⤷  Sign Up
Cyprus 743 Substituted phenylalkanoic acids and derivatives thereof ⤷  Sign Up
Finland 54099 ⤷  Sign Up
Sweden 398639 FORFARANDE FOR FRAMSTELLNING AV SUBSTITUERADE FENYLALKANSYRAFORENINGAR ⤷  Sign Up
Luxembourg 59302 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.